Kourtney Kardashian’s Lemme rolls out “GLP-1” weight loss supplement: The move is ingenious from a marketing perspective. But the brand could find itself in drugmakers’ crosshairs with already confusing marketing about the supplement’s key ingredient.

Noom gets into compounded GLP-1s with a taper-off guarantee: It’s building a weight loss program around the idea that patients will eventually want to stop taking the medications. We explore the pros and cons.

Retail media has been buoyed by consumer packaged goods companies and grocery brands looking to get their products in front of shoppers closer to the point of purchase. But now, other categories are looking to join the party: nonendemic advertisers.

Digital therapeutics (DTx) were gaining popularity as tools to help slash the US’ $3 trillion annual spending on chronic disease, and the pandemic has vaulted digital therapies into the spotlight. Now, the Teladoc-Livongo megamerger is heating up competition in the DTx space as players race to capture a slice of a market slated to reach $56 billion by 2025.